One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Dafydd R. Owen, Charlotte M. N. Allerton, Annaliesa S. Anderson, Lisa M. Aschenbrenner, Melissa Avery, Simon Berritt, Britton W. Boras, Rhonda D. Cardin, Anthony A. Carlo, Karen J. Coffman and 33 more
Path to another drug against COVID-19 The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen et al . report the discovery and characterization of a drug against the main protease involved in the cleavage of polyproteins involved in viral replication. The drug, PF-07321332, can be administered orally, has good selectivity and safety profiles, and protects against infection in a mouse model. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies. It also inhibited other coronaviruses, including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus, and could be in the armory against future viral threats. —VV
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L. M., Avery, M., Berritt, S., Boras, B. W., Cardin, R. D., Carlo, A. A., Coffman, K. J., Dantonio, A. L., Di, L., Eng, H. F., Ferre, R. A., Gajiwala, K., Gibson, S. A., Greasley, S. E., Hurst, B. L., Kadar, E. P., … Zhu, Y. (2021). An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science, 374(6575), 1586–1593. https://doi.org/10.1126/science.abl4784
Owen, Dafydd R., et al. "An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19." Science, vol. 374, no. 6575, 2021, pp. 1586–1593, https://doi.org/10.1126/science.abl4784.
Owen, Dafydd R., Charlotte M. N. Allerton, Annaliesa S. Anderson, Lisa M. Aschenbrenner, Melissa Avery, Simon Berritt, Britton W. Boras, et al. "An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19." Science 374, no. 6575 (2021): 1586–1593. https://doi.org/10.1126/science.abl4784.
Owen D. R., Allerton C. M. N., Anderson A. S. [и др.] An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 // Science. — 2021. — Vol. 374, № 6575. — P. 1586–1593. — URL: https://doi.org/10.1126/science.abl4784
@article{owen2021oral,
title = {{An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19}},
author = {Dafydd R. Owen and Charlotte M. N. Allerton and Annaliesa S. Anderson and Lisa M. Aschenbrenner and Melissa Avery and Simon Berritt and Britton W. Boras and Rhonda D. Cardin and Anthony A. Carlo and Karen J. Coffman and Alyssa L. Dantonio and Li Di and Heather F. Eng and Rose Ann Ferre and K.S. Gajiwala and Scott A Gibson and Samantha E. Greasley and Brett L. Hurst and Eugene P. Kadar and Amit S.S. Kalgutkar and Jack C Lee and Jisun Lee and Wei Yong Liu and Stephen W. Mason and Stephen Noell and Jonathan J. Novak and Ronald Scott Obach and Kevin Ogilvie and Nandini C. Patel and Martin Pettersson and Devendra K Rai and Matthew R. Reese and M. F. Sammons and Jean G. Sathish and Ravi Shankar Prasad Singh and Claire M. Steppan and Albert Stewart and Jamison B. Tuttle and Lawrence W. Updyke and Patrick R. Verhoest and Liuqing Wei and Qingyi Yang and Yuao Zhu},
journal = {Science},
year = {2021},
volume = {374},
number = {6575},
pages = {1586--1593},
doi = {10.1126/science.abl4784},
url = {https://doi.org/10.1126/science.abl4784}
}TY - JOUR AU - Owen, Dafydd R. AU - Allerton, Charlotte M. N. AU - Anderson, Annaliesa S. AU - Aschenbrenner, Lisa M. AU - Avery, Melissa AU - Berritt, Simon AU - Boras, Britton W. AU - Cardin, Rhonda D. AU - Carlo, Anthony A. AU - Coffman, Karen J. AU - Dantonio, Alyssa L. AU - Di, Li AU - Eng, Heather F. AU - Ferre, Rose Ann AU - Gajiwala, K.S. AU - Gibson, Scott A AU - Greasley, Samantha E. AU - Hurst, Brett L. AU - Kadar, Eugene P. AU - Kalgutkar, Amit S.S. AU - Lee, Jack C AU - Lee, Jisun AU - Liu, Wei Yong AU - Mason, Stephen W. AU - Noell, Stephen AU - Novak, Jonathan J. AU - Obach, Ronald Scott AU - Ogilvie, Kevin AU - Patel, Nandini C. AU - Pettersson, Martin AU - Rai, Devendra K AU - Reese, Matthew R. AU - Sammons, M. F. AU - Sathish, Jean G. AU - Singh, Ravi Shankar Prasad AU - Steppan, Claire M. AU - Stewart, Albert AU - Tuttle, Jamison B. AU - Updyke, Lawrence W. AU - Verhoest, Patrick R. AU - Wei, Liuqing AU - Yang, Qingyi AU - Zhu, Yuao TI - An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 JO - Science VL - 374 IS - 6575 SP - 1586 EP - 1593 PY - 2021 DA - 2021/11/02 DO - 10.1126/science.abl4784 UR - https://doi.org/10.1126/science.abl4784 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.